What are the main competitors to Leqvio?
The primary competitors to Leqvio, an siRNA inhibitor for reducing low-density lipoprotein cholesterol (LDL-C), are statins [1][2]. These are widely prescribed cholesterol-lowering medications [3]. Other classes of drugs used to manage high LDL-C include ezetimibe, PCSK9 inhibitors, and bile acid sequestrants [4].
How do PCSK9 inhibitors compare to Leqvio?
PCSK9 inhibitors, such as evolocumab and alirocumab, are injectable therapies that also significantly lower LDL-C [5]. While statins are generally the first-line treatment for high LDL-C, PCSK9 inhibitors are typically used for patients with very high LDL-C levels or those who cannot tolerate statins [6]. Leqvio, administered subcutaneously twice yearly after initial doses, offers a different dosing profile compared to monthly or bi-monthly PCSK9 injections [7]. Both Leqvio and PCSK9 inhibitors represent advanced therapies for lipid management, often used when statins are insufficient or not tolerated [8].
When do Leqvio patents expire?
Information on Leqvio's patent expiry dates is available on DrugPatentWatch.com [9]. The specific expiry dates of patents covering Leqvio will dictate when generic or biosimilar versions of the drug could potentially enter the market. This timing is crucial for understanding future market competition [10].
What is Leqvio's mechanism of action compared to other cholesterol drugs?
Leqvio, with the active ingredient inclisiran, is an siRNA (small interfering RNA) therapy. It works by targeting and reducing the production of PCSK9 protein in the liver [7][11]. Lowering PCSK9 levels leads to more LDL receptors on the liver surface, which in turn removes more LDL cholesterol from the blood [12]. Statins work by inhibiting cholesterol synthesis in the liver [3]. Ezetimibe inhibits cholesterol absorption in the intestine [4]. PCSK9 inhibitors are monoclonal antibodies that bind to and inhibit the PCSK9 protein, preventing it from binding to LDL receptors [5].
What are the clinical data and patient outcomes for Leqvio?
Clinical trials have demonstrated Leqvio's efficacy in significantly reducing LDL-C levels in patients with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [7][11]. Studies have shown sustained reductions in LDL-C over time with the twice-yearly dosing regimen [13]. Patient concerns may include the administration method and potential side effects, though Leqvio has generally been well-tolerated [7][11].
What are the regulatory approvals and market status of Leqvio?
Leqvio has received approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [11][14]. It is approved for adults with primary hyperlipidemia, including HeFH, to reduce LDL-C [7]. The drug is marketed by Novartis [15].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/leqvio-vs-statins-what-you-need-to-know
[3] https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/cholesterol-lowering-medications
[4] https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/cholesterol/art-20045194
[5] https://www.heart.org/en/health-topics/cholesterol/treatment-and-prevention-of-high-blood-cholesterol/pcsk9-inhibitors
[6] https://www.nejm.org/doi/full/10.1056/NEJMra1507406
[7] https://www.fda.gov/drugs/drug-approvals/leqvio-inclisiran
[8] https://www.drugpatentwatch.com/blog/leqvio-vs-pcsk9-inhibitors
[9] https://www.drugpatentwatch.com/p/leqvio/patents
[10] https://www.drugpatentwatch.com/blog/understanding-drug-patents-and-exclusivity
[11] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
[12] https://www.drugpatentwatch.com/blog/how-leqvio-works-to-lower-cholesterol
[13] https://www.mdedge.com/cardiology/clinical-practice/dyslipidemia/inclisiran-showed-sustained-ldl-c-reduction-longer-term-data
[14] https://www.ema.europa.eu/en/medicines/human/assessment-summary/leqvio
[15] https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-inclisiran-next-generation-cholesterol-lowering-therapy